US Pharma MarketingSangamo’s three-decade run comes to a close as Lilly and Astellas eye assets
Sangamo Therapeutics files for bankruptcy after three decades, selling assets to Eli Lilly for $50M and Astellas for up to $50M, ending its run as a pioneer in gene editing. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the…
Despite being an early player in the gene editing field and developing numerous clinical programs, Sangamo Therapeutics will be selling off its parts without materializing any approved therapies.
Sangamo
Source: Endpoints News